A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects

Pfizer

Status and phase

Completed

Phase 1

Conditions

Rheumatoid Arthritis

Treatments

Drug: Treatment B

Drug: Treatment A

Study type

Interventional

Funder types

Industry

Identifiers

NCT01184001

A3921076

Details and patient eligibility

About

In this study, a 10 mg tasocitinib (CP-690,550) tablet will be administered to healthy subjects on two separate dosing occasions. On one occasion the tasocitinib (CP-690,550) tablet will be administered in a fasting condition; On the other occasion the tasocitinib (CP-690,550) tablet will be administered in a fed condition following a standard breakfast meal. The amount of tasocitinib (CP-690,550) in the blood will be measured at various times over 24 hours following each dosing occasion and compared to evaluate for any differences.

Full description

To evaluate the effect of food on the pharmacokinetics of tasocitinib (CP-690,550).

Enrollment

16 patients

Sex

All

Ages

21 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy male and/or female (non-childbearing potential) subjects between the ages of 21 and 55 years.
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight for males>50 kg (110 lbs). For females, total body weight >45 kg (99 lbs).
No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

Exclusion criteria

Evidence or history of any clinically significant illness, medical condition, or disease.
Evidence or history of any clinically significant infections within the past 3 months.
Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.